HK1185261A1 - Adenovirus ad36 e4orf1 protein for prevention and treatment of non- alcoholic fatty liver disease ad36e4orf1 - Google Patents

Adenovirus ad36 e4orf1 protein for prevention and treatment of non- alcoholic fatty liver disease ad36e4orf1

Info

Publication number
HK1185261A1
HK1185261A1 HK13112652.9A HK13112652A HK1185261A1 HK 1185261 A1 HK1185261 A1 HK 1185261A1 HK 13112652 A HK13112652 A HK 13112652A HK 1185261 A1 HK1185261 A1 HK 1185261A1
Authority
HK
Hong Kong
Prior art keywords
ad36e4orf1
adenovirus
prevention
treatment
liver disease
Prior art date
Application number
HK13112652.9A
Other languages
English (en)
Chinese (zh)
Inventor
Nikhil Dhurandhar
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of HK1185261A1 publication Critical patent/HK1185261A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK13112652.9A 2010-07-08 2013-11-12 Adenovirus ad36 e4orf1 protein for prevention and treatment of non- alcoholic fatty liver disease ad36e4orf1 HK1185261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36244310P 2010-07-08 2010-07-08
PCT/US2011/043338 WO2012006512A1 (en) 2010-07-08 2011-07-08 Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
HK1185261A1 true HK1185261A1 (en) 2014-02-14

Family

ID=44629893

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13112652.9A HK1185261A1 (en) 2010-07-08 2013-11-12 Adenovirus ad36 e4orf1 protein for prevention and treatment of non- alcoholic fatty liver disease ad36e4orf1

Country Status (12)

Country Link
US (2) US8951980B2 (ja)
EP (1) EP2590665B1 (ja)
JP (1) JP5965397B2 (ja)
KR (1) KR101831638B1 (ja)
CN (1) CN103052397B (ja)
AU (1) AU2011274537B9 (ja)
CA (1) CA2803787C (ja)
ES (1) ES2550962T3 (ja)
HK (1) HK1185261A1 (ja)
NZ (1) NZ606236A (ja)
TW (1) TWI531650B (ja)
WO (1) WO2012006512A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909216B1 (en) 2012-10-17 2016-12-21 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Compositions and methods for improving glucose uptake
US9354963B2 (en) * 2014-02-26 2016-05-31 Microsoft Technology Licensing, Llc Service metric analysis from structured logging schema of usage data
EP3134417B1 (en) 2014-04-23 2019-07-31 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Small molecule analogs of e4orf1
GB201910299D0 (en) * 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354097T1 (de) * 2004-08-12 2007-03-15 Hoffmann La Roche Verfahren zur diagnose von leberfibrose.
US20060045919A1 (en) 2004-08-27 2006-03-02 Samueli Institute Homeopathic compositions and methods for the treatment of cancer
JP2008105945A (ja) * 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
EP1954131B1 (en) * 2005-11-30 2014-04-02 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Adenovirus 36 e4 orf 1 gene and protein and their uses
AU2006342053A1 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
JP2008273938A (ja) * 2007-03-30 2008-11-13 Shiseido Co Ltd アディポネクチン産生促進剤

Also Published As

Publication number Publication date
JP2013531681A (ja) 2013-08-08
US20170340699A1 (en) 2017-11-30
WO2012006512A1 (en) 2012-01-12
CA2803787C (en) 2018-12-04
EP2590665B1 (en) 2015-09-16
CA2803787A1 (en) 2012-01-12
JP5965397B2 (ja) 2016-08-03
US20120027845A1 (en) 2012-02-02
CN103052397B (zh) 2017-09-19
AU2011274537B9 (en) 2017-02-23
CN103052397A (zh) 2013-04-17
TW201217529A (en) 2012-05-01
US8951980B2 (en) 2015-02-10
ES2550962T3 (es) 2015-11-13
KR101831638B1 (ko) 2018-02-23
NZ606236A (en) 2014-09-26
EP2590665A1 (en) 2013-05-15
KR20130100262A (ko) 2013-09-10
AU2011274537A1 (en) 2013-02-14
TWI531650B (zh) 2016-05-01
AU2011274537B2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
IL267342B (en) Antibodies and preparations containing them for the treatment of cancer
IL231512A0 (en) Preparations of galacto-rhamnogalacturonate for the treatment of non-alcoholic steatohepatitis and alcoholic fatty liver disease
EP2549997A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS AND METHOD FOR THE PREVENTION OR TREATMENT OF NON ALCOHOLIC HEALING STEATOSIS USING THE SAME
HK1199220A1 (en) Pharmaceutical composition for the prevention or treatment of non- alcoholic fatty liver disease
IL225507A0 (en) Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastasis
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2532743A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
ZA201105472B (en) Methods and compositions for diagnosis and treatment of cancer
EP2550263A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
EP2567241A4 (en) DETECTION AND MONITORING OF NON-ALCOHOLIC FATERS
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
HK1185261A1 (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non- alcoholic fatty liver disease ad36e4orf1
EP2420515A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
WO2012003421A9 (en) Combinational compositions and methods for treatment of cancer
DK2665746T3 (en) Antibodies against the s100p protein for the treatment and diagnosis of cancer
TH136549B (th) เครื่องดื่มโปรตีน และวิธีการของการเตรียมของเครื่องดื่มนี้

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200714